TM6SF2 and metabolic dysfunction-associated steatotic liver disease: However, TM6SF2 knockdown significantly increased in lysoPC and lysoPE, both of which were recently identified as early biomarkers of NAFLD and are increased in NALFD patients with hepatitis [22].